Abstract: The present invention relates to method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200, wherein the compound to be detected and/or quantified is a chemically complex molecule, wherein said chemically complex molecule is substituted with at least two groups R, wherein each R group means independently —OH, —OP(O)(OH)2 or —P(O)(OH)2, with the proviso that at least two R are independently selected from —P(O)(OH)2 and —OP(O)(OH)2, wherein the compound or compounds to be detected and/or quantified are within a biological matrix, wherein said biological matrix is a biological fluid, a biological tissue, stomach contents, intestine contents, stool sample or a culture cells, wherein the method comprises performing a chromatography and identifying the retention time and/or the intensity of the signal by means of a mass or radioactivity detector.

Abstract: The present invention relates to a method for producing a domain antibody in a yeast, wherein the formation of disulfide bridges in the domain antibody is promoted. The method encompasses the addition of oxidizing agents, preferably oxidizing metal ions, preferably one or more selected from Cu2+, Fe2+, Fe3+ and Zn2+.

Abstract: Disclosed in the present invention are a stabilizer for a color developing agent and application thereof, an application of a composition in preparation of the stabilizer, and a kit. A stabilizer for a color developing agent is provided in the present invention. The stabilizer includes a reducing substance and a weakly acidic buffer, and the weakly acidic buffer has a pH of 3.8-6.2. The reducing substance includes one or more of sodium sulfite, sodium bisulfite, sodium thiosulfate, or 1-mercaptoglycerol. The color developing agent includes one or two of a phenothiazine color developing agent or a triphenylmethane color developing agent. The color developing agent can be stably preserved by using the stabilizer. A method for stably preserving a color developing agent includes dissolving the color developing agent in the stabilizer.

Abstract: Methods to treat cancer in a subject comprising administering to the subject a therapeutically effective amount of T-cells of the subject having increased IRF4 polypeptide expression compared to a control are disclosed. Also disclosed are methods of increasing tumor reactivity of a T-cell by increasing IRF4 polypeptide expression, and methods to predict the likelihood that a subject having cancer will respond therapeutically to administered T-cells having increased IRF4 polypeptide expression. Also disclosed are compositions comprising a T-cell and a viral vector encoding an IRF4 polypeptide. The compositions are methods are useful for treating numerous cancers in which higher level expression of IRF4 in T-cells would be beneficial. In some embodiments, activated tumor specific T-cells having increased IRF4 expression have greater infiltration in tumors and enhanced local immunological responses.

Abstract: A prostaglandin production method according to the present invention comprises reacting an unsaturated fatty acid with cyclooxygenase in the presence of a reducing agent. According to the present invention, it is possible to produce prostaglandins at a high yield.

Abstract: Disclosed herein are processes for obtaining a microbial oil comprising one or more polyunsaturated fatty acids (PUFAs) from one or more microbial cells by lysing the cells to form a lysed cell composition, treating the lysed cell composition to form an oil-containing emulsion and then recovering the oil from the oil-containing emulsion. Further disclosed herein is microbial oil comprising one or more PUFAs that is recovered from microbial cells by at least one process described herein.

Abstract: The present invention includes methods and systems for assessing a cellular response to a treatment modality, such as potential drug candidate, by comparing normalized single-cell measurements of cellular properties without the need of a calibration step.

Abstract: This invention provides for an improved method of stabilizing freeze dried bacterial extracts with a carbohydrate lyoprotectant such that the extracts can be for use in cell free protein synthesis. Also provided herein are formulations for stable, freeze dried bacterial extracts that when stored at room temperature retain at least about 70% protein synthesis activity compared to undried frozen bacterial extracts.

Abstract: Disclosed is a use of a cell wall skeleton of isolated Rhodococcus ruber or a composition containing the same for preparing a human papillomavirus infection treatment drug. The cell wall skeleton of Rhodococcus ruber isolated from Rhodococcus ruber was stored and preserved at China General Microbiological Culture Collection Center, No. 1, West Beichen Road, Chaoyang District, Beijing on Mar. 22, 2019 with accession number CGMCC 17431.

Abstract: A method for preparing glucosamine includes the steps of converting fructose-6-phosphate (F6P) and an ammonium salt to glucosamine-6-phosphate (GlcN6P) under the catalysis of glucosamine-6-phosphate deaminase (EC 3.5.99.6, GlmD); and producing glucosamine (GlcN) by the dephosphorylation of GlcN6P under the catalysis of an enzyme capable of catalyzing the dephosphorylation. Such a method can be used to prepare glucosamine by in vitro enzymatic biosystem.

Abstract: Methods of treatment are provided herein, including administration of a population cells modified to enforce expression of an E-selectin and/or an L-selectin ligand, the modified cell population having a cell viability of at least 70% after a treatment to enforce such expression.

Abstract: Described are methods for the production of isobutene comprising the enzymatic conversion of 3-methylcrotonic acid into isobutene wherein the enzymatic conversion of 3-methylcrotonic acid into isobutene is achieved by making use of an FMN-dependent decarboxylase associated with an FMN prenyl transferase, wherein said FMN prenyl transferase catalyzes the prenylation of a flavin cofactor (FMN or FAD) utilizing dimethylallyl phosphate (DMAP) into a flavin-derived cofactor, wherein said method further comprises providing said DMAP enzymatically by: (i) the enzymatic conversion of dimethylallyl pyrophosphate (DMAPP) into said DMAP; or (ii) a single enzymatic step in which prenol is directly enzymatically converted into said DMAP; or (iii) two enzymatic steps comprising: first enzymatically converting DMAPP into prenol; and then enzymatically converting the thus obtained prenol into said DMAP; or (iv) the enzymatic conversion of isopentenyl monophosphate (IMP) into said DMAP, or by a combination of any one of (i) t

Abstract: A method for screening substances for their ability to reduce malodours from emanations from an animal, said method comprising determining the effect of said substances on the C-S lyase activity of bacteria that emit volatile sulphuric compounds (VSCs), by contacting a test substance with a sample comprising said bacteria or a supernatant obtainable from a culture of said bacteria in the presence of a substrate for a C-S lyase, detecting the levels of thiol production from said bacteria, and comparing the results with those obtained from similar bacteria in the absence of said substance.

Abstract: The present invention relates to novel process for the production of ketoisophorone via biocatalytic conversion of isophorone, in particular a one-pot biocatalytic system for conversion of ?-isophorone in a two-step oxidation process, with a first oxidation being catalyzed by a heme containing oxidoreductase such as a cytochrome P450 monooxygenase followed by another oxidation which can be either a chemical reaction or a biocatalytic reaction, in particular wherein the oxidation is catalyzed by an NAD(P) or NADP(H)-dependent oxidoreductase. The invention further provides polypeptides and nucleic acid sequences coding for cytochrome P450 monooxygenase with modified (higher) substrate selectivity, total turnover numbers and/or (re)activity compared to the wild-type enzyme. Ketoisophorone is useful as building block in the synthesis of vitamins and carotenoids.

Abstract: The present invention provides methods of treating LAL deficiency comprising administering to a mammal a therapeutically effective amount of lysosomal acid lipase with an effective dosage frequency. Methods of improving growth and liver function, increasing LAL tissue concentration, and increasing LAL activity in a human patient suffering from LAL deficiency are also provided.

Abstract: A method of controlling or preventing pathogenic damage and/or pest damage in a plant propagation material, a plant, part of a plant and/or plant organ, comprising applying on the plant, part of the plant, plant organ, plant propagation material or a surrounding area thereof a phytoprotective agent comprising an enzyme and a fungicide.

Abstract: A fermentation broth which includes a microbial cell which has been subjected to a condition under which the activity an endogenous transporter for 2? fucosyllactose is increased. Also provided are methods for increasing export of 2? fucosyllactose from a microbial cell, methods for identifying an endogenous yeast transporter of 2? fucosyllactose, and microbial cells genetically engineered to increase the activity of an endogenous transporter of 2? fucosyllactose.

Abstract: A process includes growing NRB in a nitrate reducing bacteria media to form a NRB culture and combining the NRB culture with a concentrated nitrate solution to form a NRB composition.

Abstract: In some embodiments, the present disclosure provides an apparatus and methods for selectively lysing cells from a cell suspension including disassociating a population of cells from a tissue sample, the population of cells including a population of one or more viable cells and a population of one or more dead and dying cells, exposing the population of cells to at least one pulse of fluid shear stress having a force along a conduit wall of from about 500 dyn/cm2 to about 2500 dyn/cm2 to substantially lyse the population of one or more dead or dying cells, leaving the population of one or more viable cells substantially intact, and collecting the population of one or more viable cells.

Abstract: Disclosed are a method and a reagent for quantifying HDL3 in a test sample without requiring laborious operations. The method for quantifying cholesterol in high-density lipoprotein 3 comprises reacting a test sample with one or more surfactants which react specifically with high-density lipoprotein 3, and quantifying cholesterol. When one surfactant is used, the surfactant is one selected from the group consisting of polyoxyethylene polycyclic phenyl ethers having an HLB of 12.5 to 15. When two or more surfactants are used, at least one of the surfactants is at least one selected from the group consisting of polyoxyethylene polycyclic phenyl ethers, and the two or more surfactants are combined so as to provide the total HLB of 12.5 to 15 of the combined surfactants.